BRYAN, Texas, Nov. 29, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced an update for its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron (B.1.1.529) variant of SARS-CoV-2.
BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) — iBio, Inc., a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced a research collaboration with the University of Texas Southwestern Medical Center (“UT Southwestern”) to explore in solid tumors the anti-cancer potential of the molecule that is part of the IBIO-100 program.
BRYAN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming System, today announced it has purchased the manufacturing facility it previously operated under a lease from two affiliates of Eastern Capital Limited (the “Eastern Affiliates”). The Company also acquired the approximate 30% equity interest in iBio CDMO, LLC. (the “CDMO”) held by the Eastern Affiliates. As a result, the subsidiary and its intellectual property are now wholly-owned by iBio.
SAN DIEGO and BRYAN, Texas, Aug. 25, 2021 (GLOBE NEWSWIRE) — iBio, Inc., a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced that it has signed a definitive worldwide exclusive license agreement with RubrYc Therapeutics, Inc., for RTX-003, an immunotherapy candidate targeting regulatory T cells (Tregs).
BRYAN, Texas, July 15, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein (“N protein”) of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell response. Data on commercially available COVID-19 …